PubMed ID:
28758155
Public Release Type:
Journal
Publication Year: 2017
DOI:
https://doi.org/10.1016/j.ekir.2017.03.008
Authors:
Freedman Barry I., Rocco Michael V., Bates Jeffrey T., Chonchol Michel, Hawfield Amret T., Lash James P., Papademetriou Vasilios, Sedor John R., Servilla Karen, Kimmel Paul L., Wall Barry M., Pajewski Nicholas M.
Request IDs:
20241
,
20271
,
20272
Studies:
African American Study of Kidney Disease and Hypertension Study (Clinical Trial)
Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, a total of 2568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were assessed for the incidence of CVD events (primary composite including nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and CVD death), renal outcomes, and all-cause mortality.